Background {#Sec1}
==========

Colorectal cancer (CRC) is the third most common cancer worldwide \[[@CR1]\]. Due to the heterogeneity of the disease, various factors are proven to be associated with the prognosis in CRC patients. The Cancer Genome Atlas (TCGA) program classified CRC into two large groups: chromosomal instability (CIN) and microsatellite instability (MSI) \[[@CR2]\]. MSI is the alteration of the size of nucleotide repeat sequence named microsatellites, which is caused by the loss-of-function of mismatched repair (MMR) gene; leading to the inability to repair DNA mismatches and accounted for approximately 15 to 20% of CRC patients.

The National Comprehensive Cancer Network (NCCN) guidelines \[[@CR3]\] stated that stage II MSI-H patients have a better prognosis and do not benefit from fluorouracil (5-FU) adjuvant therapy \[[@CR4]\]. Unlike microsatellite-stable (MSS) CRCs, MSI-H not only had a much more active immune microenvironment with greater tumor-infiltrating lymphocytes (TIL), but also showed cancer-specific upregulation of inhibitory checkpoints including programmed cell death protein 1 (PD-1) and CTLA4 \[[@CR5]\]. Therefore, unlike MSS CRCs, MSI-H CRCs showed a much better response to checkpoint immunotherapy. It is interesting to note that there are lots of controversies about whether microsatellite instability-high (MSI-H) is a good prognostic factor in stage III and stage IV CRC patients. Some studies proved that MSI-H is still a beneficial factor with better oncological survival \[[@CR6], [@CR7]\]. However, several researches came to opposite conclusions, indicating MSI-H as an adverse factor for both overall survival (OS) and cancer-related survival \[[@CR8]\].

MSI status can be confirmed by polymerase chain reaction (PCR) with the results of MSI-H or MSS. However, the PCR method is expensive and complicated, while immunohistochemistry(IHC) method is cheap, convenient, and widely used \[[@CR9]\]. IHC can prove whether there is a mismatch repair deficiency (dMMR) that indicates a similar situation as MSI-H, and previous research has proved that these two methods have excellent agreement \[[@CR10]\].

In order to further explore the prognostic value of MSI-H in stage III and stage IV colorectal cancer patients, a comprehensive meta-analysis was performed.

Materials and methods {#Sec2}
=====================

Two authors searched the PubMed electronic database, Cochrane Central Library database, and Embase for available articles that were published before July 2018. Search terms covered four aspects considering the variants of the following keywords, which included "colorectal cancer," "microsatellite instability," "advanced stage," and "survival." The PubMed search terms are listed as follows: (((((((Colonic Neoplasms) OR Colorectal Neoplasms) OR Colorectal cancer) OR colon cancer)) AND (((((Microsatellite Instability) OR Microsatellite Repeats) OR MSI) OR Mismatch repair) OR dMMR)) AND (((((((Neoplasm Metastasis) OR lymphatic metastasis) OR late stage) OR stage III OR stage IV OR advanced stage) OR metastasis)) AND ((((((prognosis) OR mortality) OR survival) OR OS) OR DFS) OR outcome). The search strategy was modified accordingly for the Cochrane Central Library database and Embase.

Inclusion criteria were listed as follows: Original articles, with retrievable survival data in full text or abstract, that compare the clinical outcome between MSI-H and MSS in stage III or stage IV CRC.From the abstract or full text, hazard ratio (HR) of OS, disease-free survival (DFS), or other survival rates between MSI-H and MSS groups, can be acquired, or calculated.

Also, research that matched any of the criteria below were excluded to prevent bias. Patients who received immunotherapy such as anti-PD-1 or anti-programmed death-ligand 1 (PD-L1) treatment.When the number of patients in the MSI-H group was less than 9.Research that included other factors (such as BRAF status) that mixed with microsatellite status and could not calculate the HR separately.

The search and analysis procedures were performed by two authors separately. If multiple researches were used to investigate the patients in the same clinical trial or medical institution, the latest or largest one will be included in order to prevent overlapping. We also excluded letters, review articles, and case reports. If the two authors had a disagreement, a third reviewer made the decision.

The included studies comprised of both RCT and non-RCT studies; therefore, both Cochrane and Newcastle--Ottawa scale were used to assess the methodological quality

Statistical analysis and data synthesis {#Sec3}
---------------------------------------

Considering the different clinical survivals in stage III and IV CRC, the analysis for OS, DFS, and disease-specific survival (DSS) were performed separately according to the different stages.

The adjusted log hazard ratios (HRs) were used to estimate the prognostic value between MSI-H and MSS CRCs. The HRs were extracted from the Cox proportional hazards regression model provided in the included articles. For studies that failed to provide the HR value between MSI-H and MSS groups but provided the Kaplan-Meier survival curves, Engauge Digitizer (Version 4.1) was used to extract the survival information from the curve while HR was calculated by the method provided by Tierney et al. \[[@CR11]\]

Meta-analysis was performed between MSI-H and MSS patients to explore the relationship between microsatellite status and clinical prognosis, using Stata version 14.0 (Stata, College Station, TX).

Heterogeneity was quantified using the *I*^2^ statistic. The random-effects model was conducted to estimate the pooled effect size of OS, DFS, and DSS. Funnel plots were performed in every analysis to examine publication bias. Sensitivity analysis was also performed in every subgroup analysis. Meta-regression analysis was performed to control for heterogeneity. The DFS is usually defined based on the "study entry till documented progression or death from any cause," while relapse-free survival (RFS) and progression-free survival (PFS) showed similar endpoints. Therefore, these data were analyzed together. For the same season, we combined the DSS and cancer-specific survival (CSS).

The RCT studies were assessed according to the Cochrane protocol. The non-RCT studies were assessed using the Newcastle--Ottawa scale which considers participant selection, comparability, and outcome with a full score of 9. A score higher than 6 was considered to be of good quality for the individual study.

Results {#Sec4}
=======

Overall, 847, 425, and 62 studies were retrieved from PubMed electronic database, Embase, and Cochrane Library, respectively. After the removal of duplicate articles, a total of 838 papers that matched the inclusion criteria were found. In total, 748 papers were excluded following the reading of the title and abstract. The full text of the remaining 90 articles was carefully read by two authors. Several researches were excluded due to the inability to acquire the specific survival data. Finally, 36 articles, that provided specific survival information, were included in this meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). Fig 1Flow diagram of researches screening

Characteristics of the studies {#Sec5}
------------------------------

The characteristics of the studies are summarized in Table [1](#Tab1){ref-type="table"}. For stage III CRC, seven \[[@CR6], [@CR8], [@CR10], [@CR33], [@CR34], [@CR36], [@CR39]\] RCTs had survival information for both OS and DFS; and an extra article \[[@CR40]\] was available for DFS analysis. There were 13 \[[@CR7], [@CR15], [@CR16], [@CR18], [@CR19], [@CR21], [@CR23], [@CR25], [@CR29], [@CR32], [@CR41], [@CR43], [@CR44]\] non-RCT studies that provided information on OS HR or available data while 11 \[[@CR15], [@CR18], [@CR19], [@CR21], [@CR23]--[@CR25], [@CR32], [@CR37], [@CR42], [@CR43]\] were found for DFS analysis. Five researches \[[@CR13], [@CR20], [@CR28], [@CR29], [@CR37]\] also provided DSS/CSS information. For stage IV, only two RCTs \[[@CR30], [@CR31]\] for OS were available, with eight non-RCTs \[[@CR12], [@CR14], [@CR17], [@CR22], [@CR25]--[@CR27], [@CR38]\]. No available RCT data for DFS analysis and five non-RCT \[[@CR22], [@CR25]--[@CR27], [@CR30]\] articles were included. Five studies \[[@CR13], [@CR20], [@CR28], [@CR29], [@CR37]\] have CSS/DSS information and were analyzed together. The MSI could be measured by both PCR and IHC, different researches performed different methods as shown in Table [1](#Tab1){ref-type="table"}. Cochrane risk of bias and Newcastle--Ottawa scale results are shown in Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}; both of them showed no obvious risk of bias. Table 1Characteristics of the included studiesAuthorCountryYearStudy designStageTotal no.MSI-HMSSMSI determinationSurvival informationChemotherapyAlex, A.K \[[@CR12]\]Brazil2017Non-RCTIV1264284IHC + PCROSOxaliplatin-basedBertagnolli \[[@CR10]\]USA2009RCTIII70296606IHC + PCROS, DFSFU/LV/IFLChouhan \[[@CR13]\]Australia2018Non-RCTIII68695591IHC + PCRCSSNAdes Guetz \[[@CR14]\]France2007Non-RCTIV40931PCROSFOLFOXDrucker \[[@CR15]\]Canada2013Non-RCTIII15918141IHC + PCROS, DFSFOLFOX/capecitabineElsaleh \[[@CR16]\]Australia2001Non-RCTIII73263669PCROS5-FU/levamisoleFujiyoshi \[[@CR17]\]Japan2017Non-RCTIV40115386PCROSNAGuidoboni \[[@CR7]\]Italy2001Non-RCTIII542034PCROS5-FUHemminki \[[@CR18]\]Finland2000Non-RCTIII951184PCROS, DFS5-FU-basedJover \[[@CR19]\]Spain2006Non-RCTIII20918191IHC + PCROS, DFS5-FU-basedJung \[[@CR20]\]Korea2016Non-RCTIII601941PCRCSSNAKim, C.G \[[@CR21]\].Korea2016Non-RCTIII29402612679PCROS, DFS5-FU/LV/FOLFOXKim, J.E \[[@CR22]\].Korea2011Non-RCTIV19723174IHC + PCROS, DFSFOLFIRI/XELIRIKim, J.E \[[@CR23]\].Korea2017Non-RCTIII and IV79573722PCROS, DFSFOLFOXKim, S.H \[[@CR24]\].Korea2013Non-RCTIII39426368PCRDFSFOLFOXKlingbiel, D \[[@CR6]\].Switzerland2015RCTIII859104755PCROS, DFS5-FU/LV/FOLFIRILi, P \[[@CR25]\].China2017Non-RCTIII and IV59954545IHCOS, DFSFOLFOX/XELOXLiu \[[@CR26]\]China2018Non-RCTIV46130431IHC + PCROS, DFSNAMa, J \[[@CR27]\].China2015Non-RCTIV18434150IHCOS, PFSFOLFIRI/irinotecanMalesci, A \[[@CR28]\].Italy2007Non-RCTIII26427237PCRDSS5-FUMohan, H.M \[[@CR29]\].Ireland2016Non-RCTIII32032288IHC + PCROS, DSSNANopel-Dunnebacke \[[@CR30]\]Germany2014RCTIV20414190IHC + PCROS, PFSCAPOX/FUFOXNordholm-Carstensen \[[@CR31]\]Denmark2015RCTIV93575860IHCOSNAOh, S.Y \[[@CR32]\].Korea2013Non-RCTIII12716111PCROS, DFSFOLFOXSasaki, Y \[[@CR33]\].Japan2016RCTIII30423281IHCOS, RFSUFTSinicrope, F. A \[[@CR34]\]USA2011RCTIII13631801183IHC + PCROS, DFS5-FU-basedSinicrope, F.A \[[@CR35]\].USA2013RCTIII25803142266IHC + PCRDFSFOLFOX-basedTaieb, J \[[@CR36]\].France2016RCTIII17911771614IHC + PCROS, DFSFOLFOX ± cetuximabTan, W. J \[[@CR37]\].Singapore2018Non-RCTIII29927272IHCDSS, RFS5FU/capecitabine ± oxaliplatinTran, B \[[@CR38]\].Australia2011Non-RCTIV35040310IHC + PCROSNAVenderbosch, S \[[@CR8]\].Netherlands2014RCTIII30631532910IHCOS, PFSNAWatanbe \[[@CR39]\]USA2000Non-RCTIII22973156PCROS, DFS5-FU--basedWestra, J. L. \[[@CR40]\]UK2005RCTIII27322944PCRDFS5-FU--basedWright, C.M \[[@CR41]\].Australia2000Non-RCTIII23821217PCROSNAZaanan, A \[[@CR42]\].France2010Non-RCTIII23332201IHC + PCRDFSFOLFOXZaanan, A \[[@CR43]\].France2011Non-RCTIII30334269IHC + PCROS, DFSFOLFOX*MSI-H* microsatellite instability-high, *MSS* microsatellite stable, *RCT* randomized controlled trial, *IHC* immunohistochemistry, *PCR* polymerase chain reaction, *OS* overall survival, *DFS* disease-free survival, *DSS* disease-specific survival, *CSS* cancer-specific survival, *RFS* recurrence-free survival, *FU* fluorouracil, *LV* leucovorin, *IFL* irinotecan + fluorouracil + leucovorin, *5-FU* 5-fluorouracil, *FOLFOX* 5-fluorouracil + leucovorin + oxaliplatin, *FOLFIRI* 5-fluorouracil + irinotecan + leucovorin, *XELOX* xeloda + oxaliplatin, *CAPOX* capecitabine + oxaliplatin, *FUFOX* fluorouracil + fludarabine + oxaliplatin, *UFT* tegafur Fig 2Cochrane risk of bias analysis for included randomized controlled trial Table 2Newcastle--Ottawa scale for included non-RCT studiesAuthorYearStudy designSelectionComparabilityOutcometotal123412123Alex, A.K \[[@CR12]\]2017Non-RCT1111111119Chouhan \[[@CR13]\]2018Non-RCT1111101118des Guetz, G \[[@CR14]\]2007Non-RCT1111110118Drucker, A \[[@CR15]\]2013Non-RCT1111101107Elsaleh, H \[[@CR16]\]2001Non-RCT1111110118Fujiyoshi, K \[[@CR17]\]2017Non-RCT1111111018Guidoboni, M \[[@CR7]\].2001Non-RCT1111101118Hemmink i \[[@CR18]\]2000Non-RCT1111111119Jover \[[@CR19]\]2006Non-RCT1111101017Jung, S.H \[[@CR20]\].2016Non-RCT1111111119Kim, C. G \[[@CR21]\].2016Non-RCT1111101118Kim, J.E \[[@CR23]\].2017Non-RCT1111110118Kim, J.E \[[@CR22]\].2011Non-RCT1111111119Kim, S.H \[[@CR24]\].2013Non-RCT1111101017Lanza, G \[[@CR44]\].2006Non-RCT1111110107Li, P \[[@CR25]\].2017Non-RCT1111111119Liu \[[@CR26]\]2018Non-RCT1111111119Ma, J \[[@CR27]\].2015Non-RCT1111111119Malesci, A \[[@CR28]\].2007Non-RCT1111101107Mohan, H.M \[[@CR29]\].2016Non-RCT1111111119Oh, S.Y \[[@CR32]\].2013Non-RCT1111101017Tan, W. J \[[@CR37]\].2017Non-RCT1111110118Tran, B \[[@CR38]\].2011Non-RCT1111111119Wright, C. M \[[@CR41]\].2000Non-RCT1111101118Zaanan, A \[[@CR43]\].2011Non-RCT1111110006Zaanan, A \[[@CR42]\].2010Non-RCT1111110118

Data analysis {#Sec6}
-------------

Meta-analyses were performed for every subgroup according to stage, study method, and survival information. Figure [3](#Fig3){ref-type="fig"} shows the results of the RCTs while Fig. [4](#Fig4){ref-type="fig"} presents the results of the non-RCTs. Fig 3Meta-analysis of HRs between microsatellite instability-high (MSI-H) and microsatellite-stable (MSS) CRC patients in randomized controlled trials (RCTs). **a** Overall survival (OS) for stage III. **b** Disease-free survival (DFS) for stage III. **c** OS for stage IV Fig 4Meta-analysis of HRs between microsatellite instability-high (MSI-H) and microsatellite-stable (MSS) CRC patients in non-randomized controlled trials (non-RCTs). **a**--**c** Overall survival (OS); disease-free survival (DFS); disease-specific survival (DSS) for stage III. **d**--**e** OS and DFS for stage IV

Relationship between MSI and survival {#Sec7}
-------------------------------------

The RCT and non-RCT studies were analyzed separately both for stage III and stage IV groups. The analysis used OS, DFS, and DSS as the judging point. Since DFS, PFS, and RFS have very similar endpoints, their data were analyzed together. Also, DSS and CSS were analyzed together.

For stage III CRC, the calculated HR value of OS was 0.94 (95% CI 0.73--1.21) in RCT subgroup and 0.89 (95% CI 0.62--1.28) in non-RCT subgroup. For DFS, the RCT group showed HR of 0.83 (95% CI 0.65--1.07) similar to the non-RCT subgroup, 0.83 (95% CI 0.65--1.07). DSS was also calculated as 1.07 (95% CI 0.68--1.69) in the non-RCT subgroup. All these results showed that MSI-H had no beneficial effect in stage III CRC.

For stage IV CRC, the HR for OS in the RCT subgroup was 1.23 (95% CI 0.92--1.64) but only two RCTs were included. For non-RCT study, the combined HR for OS and DFS was 1.10 (95% CI 0.77--1.51) and 0.72 (95% CI 0.53--0.98), respectively. The pooled HR suggested a non-beneficial effect for OS. However, for DFS, the pooled results suggested a slight beneficial effect.

Sensitivity analysis {#Sec8}
--------------------

Sensitivity analysis was performed for all subgroups, each study was excluded to draw a new result that is shown in Fig. [5](#Fig5){ref-type="fig"}; and no obvious bias was detected in the subgroup analysis. Fig 5Sensitivity analysis for included researches. **a** Overall survival (OS) for stage III RCT studies. **b** Disease-free survival (DFS) for stage III RCT studies. **c** OS for stage III retrospective studies. **d** DFS for stage III retrospective studies. **e** Disease-specific survival (DSS) for stage III retrospective studies. **f** OS for stage IV retrospective studies. **g** DFS for stage IV retrospective studies

Publication bias was detected in all subgroups. The results are shown in the funnel plots (Fig. [6](#Fig6){ref-type="fig"}); and no obvious publication bias was detected. Fig 6Publication bias detected by funnel plots. The funnel plots showed the HR associated with MSI in included studies of different subgroups. **a** Overall survival (OS) for stage III RCT studies. **b** Disease-free survival (DFS) for stage III RCT studies. **c** OS for stage III retrospective studies. **d** DFS for stage III retrospective studies. **e** Disease-specific survival (DSS) for stage III retrospective studies. **f** OS for stage IV retrospective studies. **g** DFS for stage IV retrospective studies

Since the included studies in stage IV were limited, meta-regression analysis was performed for stage III researches. Study design and year of publication were taken into consideration. The adjusted *I*^2^ was 36.55% for OS and 51.26% for DFS, suggesting study design and year of publication to be influencing factors.

Discussion {#Sec9}
==========

For stage III CRC, neither RCTs nor retrospective studies reached a convincing conclusion. Most included RCTs had insignificant results, except Venderbosch's \[[@CR8]\] research, which showed that dMMR conferred an inferior prognosis on both DFS and OS based on a series of cohort studies including 3063 patients. On the contrary, Klingbiel et al. \[[@CR6]\] and Westra \[[@CR40]\] studies showed MSI-H to be a good factor for DFS. The synthetized analysis turned out to be inconclusive. For non-RCTs, several researches revealed statistically significant results; however, the pooled result failed to draw a positive result.

For stage IV CRC, there were only two RCTs available \[[@CR30], [@CR31]\] on OS, both of which showed no positive results. Retrospective studies also showed no conclusive results of the predictive effect on OS. This indicates MSI-H/dMMR not to be predictive factor of a better prognosis. For DFS, the only RCT \[[@CR30]\] showed no survival difference (*p* = 0.47) between MSI-H and MSS group. Non-RCT researches revealed a significant beneficial result, but the included researches were limited and the number of MSI-H patients was few, making the result less convincing. Another point was that the definition of stage IV was too wide and the survival rate about whether a patient can achieve "no evidence of disease" (NED) differed greatly. It was discovered that in most studies, NED patients were not separated from non-surgical patients during analysis, several studies only included unresectable patients, making the results of stage IV less convincing. Therefore, whether MSI-H is beneficial for stage IV DFS needs further exploration with large scale RCTs.

To our knowledge, this meta-analysis is the first to summarize the prognostic effect of MSI-H CRC in an advanced stage. The result showed that MSI-H may not be a good prognostic factor for stage III or stage IV CRC patients.

Although MSI-H CRC accounted for only about 15% of all CRC patients, this special molecular subtype has a distinctly different pathological manifestation including poor differentiation, accumulation of lymphocytes, and intertumoral heterogeneity. The NCCN guideline indicates that stage II MSI-H patients may have a good prognosis and do not benefit from 5-FU adjuvant therapy \[[@CR3]\]. For stage III and IV CRC, there are disagreements on whether MSI-H is a good prognostic factor.

Recent studies \[[@CR45], [@CR46]\] proved that MSI-CRCs were sensitive to immune checkpoint blockade with anti-PD1 and PD-L1 antibodies. dMMR patients have much higher somatic mutations and prominent lymphocyte infiltrates. Previous studies showed that MSI-H CRCs exhibit a strong association with tumor-infiltrating lymphocytes and the immune reaction is strongly relevant to survival \[[@CR47], [@CR48]\]. This may explain why early-stage MSI-H CRCs manifest a better clinical prognosis. Furthermore, this paradoxical phenomenon can be explained by a lot of studies focused on the immune checkpoint. While MSI-H CRCs have more tumor-infiltrating lymphocytes, scientists also found MSI-H tumor microenvironment strongly expressed several checkpoint ligands including PD-1 and CTLA-4. However, the active immune microenvironment is counterbalanced by immune inhibitory signals that resist tumor elimination \[[@CR5]\]. This may explain why stage III and IV MSI-H CRC did not manifest a better survival, it might be because the immune system has completely lost the fight against tumor cells who overexpressed PD-1 and CTLA-4, and then metastasis began \[[@CR49]--[@CR51]\]. One important thing to notice is that MSI-H has a strong relevance in the upregulation of immune checkpoint, making checkpoint inhibitor a promising treatment method \[[@CR52]\].

As mentioned above, MSI CRC accounted for about 15% of all CRC patients. However, in this meta-analysis, the percentage of MSI-H patients was 11% and 9.4% in stage III and stage IV subgroup, respectively. The lower percentage may suggest that MSI-H/dMMR CRC have a reduced potential of metastasis \[[@CR28], [@CR53]\], but the underlying mechanism is yet to be clarified. One plausible explanation could be the stronger immunoreaction of MSI-H cancer \[[@CR54]\].

Several aspects of this meta-analysis warrant further discussions. For advanced-stage CRC, chemotherapy was commonly recommended, but the chemotherapy regimen has altered a lot in recent decades; this may cause different effect on MSI-H and MSS patients. Therefore, we also analyzed the prognostic effect of different chemotherapy on these subgroups of patients; but there were no significant conclusions.

There are several limitations to this meta-analysis. First, the majority included researches that were non-RCTs due to the limited number of RCTs. Secondly, there was heterogeneity between the included studies and exaggeration may still exist even with the random-effects model. On the contrary, sensitivity analysis did not show obvious change in the pooled results, suggesting an acceptable result.

Thirdly, several researches did not provide HR, and relative survival data were extracted for the article in order to calculate the approximate HR. Although mathematically practical, this may cause a slight calculation error. Lastly, the researches focusing on stage IV CRC is very limited; therefore, this may not reach a very convincing result.

In conclusion, in contrast to stage II, MSI-H CRCs showed no good prognostic effect for OS, DFS, and DSS in stage III as well as OS for stage IV CRCs patients.
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